Overview

A Study Comparing Trifarotene Cream 0.005% to AKLIEF CREAM (US REFERENCE LISTED DRUG), AKLIEF CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

Status:
COMPLETED

Trial end date:
2024-11-09

Target enrollment:

Participant gender:

Summary

To demonstrate the efficacy, therapeutic equivalence and safety of Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and US Reference Listed Drug, Canadian Reference Product over the placebo control in the treatment of acne vulgaris.

Phase:

PHASE1

Details

Lead Sponsor:

Sun Pharmaceutical Industries, Inc.

Treatments:

trifarotene